{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:29:44Z","timestamp":1788427784554,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,1,16]],"date-time":"2015-01-16T00:00:00Z","timestamp":1421366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"This research is supported in part by the MD Anderson Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:p>Inotuzumab ozogamicin was found to be highly active in patients with refractory\u2010relapsed acute lymphocytic leukemia (ALL), with an overall response rate of 58% and a median survival of 6.3 months. Identifying factors associated with different outcomes on inotuzumab therapy may help select patients for this treatment and advice of prognosis. A total of 89 patients treated with inotuzumab on previous studies were analyzed. Inotuzumab was given at 1.3\u20131.8 mg\/m<jats:sup>2<\/jats:sup>intravenously (IV) \u00d7 1 every 3\u20134 weeks or weekly (0.8 mg\/m<jats:sup>2<\/jats:sup>day 1, 0.5 mg\/m<jats:sup>2<\/jats:sup>days 8 and 15) every 3\u20134 weeks. Pretreatment factors associated with achieving marrow complete response (CR) and with survival were analyzed using standard statistical methods. The median survival of patients with at least marrow CR was 9.2 months versus 3.4 months for those without marrow CR (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). By multivariate analysis, a high peripheral blood absolute blast count and low platelet count were independently associated with a lower likelihood of achieving at least marrow CR. Baseline characteristics independently associated with worse survival included adverse cytogenetics [complex karyotype, translocation (4;11), translocation (9;22), abnormal chromosome 17], disease beyond first salvage, and high peripheral blood absolute count. Patients with 0, 1\u20132, or 3 adverse factors had a median survival of 39+, 7.5, and 2.4 months, respectively. Our current analyses identified a subset of adult patients with ALL in whom outcome of therapy with inotuzumab ozogamicin can be differentially predicted. Am. J. Hematol. 90:193\u2013196, 2015. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ajh.23901","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T16:09:10Z","timestamp":1416326950000},"page":"193-196","source":"Crossref","is-referenced-by-count":41,"title":["Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a<scp>CD<\/scp>22 monoclonal antibody"],"prefix":"10.1002","volume":"90","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rytting","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia U.T. M.D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,1,16]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.789509"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529206"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398564"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_2_5_7_1","volume-title":"Categorical Data Analysis","author":"Agresti A","year":"1990"},{"key":"e_1_2_5_8_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non\u2010parametric estimation from incomplete observations","volume":"53","author":"Kaplan EL","year":"1965","journal-title":"J Am Stat Assoc"},{"key":"e_1_2_5_9_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox DR","year":"1972","journal-title":"J R Stat Soc"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25354"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_5_12_1","article-title":"Confirmatory open\u2010label, single\u2010arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed\/refractory B\u2010precursor acute lymphoblastic leukemia (r\/r ALL)","volume":"325","author":"Topp MS","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24862"},{"key":"e_1_2_5_16_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7019","article-title":"Inotuzumab ozogamicin (IO) in combination with low\u2010intensity chemotherapy as front\u2010line therapy for older patients and as salvage therapy for adult with relapse\/refractory acute lymphoblastic leukemia","volume":"32","author":"Jabbour E","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.7064","article-title":"Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"32","author":"O'Brien S","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23901","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T04:22:13Z","timestamp":1717561333000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,16]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1002\/ajh.23901"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23901","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,16]]}}}